HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

The semaglutide trial showed effect sizes “in the medium to large range,” he said, although he urged caution about the results since the trial “was the first to look at this question in a ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with alcohol use ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

A new study showed that semaglutide may help with alcohol use ... Over the nine-week trial, not only were alcohol cravings reduced, but when those on the medication did drink alcohol, they drank ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Semaglutide may work quickly. In a 2021 clinical trial, some participants lost more than 2% of their body weight within 4 weeks. The weight loss pattern continued, and participants lost an average ...

This trial involved participants who had obesity or overweight along with at least one weight-related health issue (excluding type 2 diabetes), who were given a 2.4 mg dose of semaglutide.

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...